A Unified Approach to Facial Contours and Volume Correction: The Role of the Cheek and the Chin.

Background

Facial proportions and contours influence perceptions of beauty and youthfulness. In particular, the shape and definition of the midface and lower face impact the overall appearance of the face.

Methods

This review provides anatomical evidence to support a holistic approach to facial analysis and rejuvenation that starts with assessment and treatment of the midface and lower face to create an aesthetically desirable facial balance.

Results

The cheek and chin can be considered "anchors" or starting points within full-face treatment because of the noticeable impact of their treatment on the definition and contour of the entire face. Age-related changes in the cheek and chin affect overall facial appearance and can produce unintended facial emotional attributes such as looking tired, angry, or sad. Patients seek facial aesthetic treatment typically for a global improvement such as revitalization or genderization of facial features. Best practices in aesthetics have evolved from treatment of individual areas to a holistic paradigm that uses multimodal therapy to improve overall facial emotional attributes. Hyaluronic acid fillers are useful for volume replacement and smoothing abrupt transitions that develop with age throughout the midface, chin, and jaw. A combination of hyaluronic acid filler for volume restoration and sodium deoxycholate and/or onabotulinumtoxinA for volume reduction where appropriate may optimize lower facial contour.

Conclusions

This review highlights the importance of facial angles and contours as well as the significance of panfacial assessments and treatment, focusing on the relationships within areas of the face, specifically the midface and lower face, to optimize results.

Informations de copyright

Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.

Déclaration de conflit d'intérêts

Dr. Moradi is a consultant, clinical research investigator, faculty member, and advisor for AbbVie; a consultant, advisor, steering committee member, European summit expert, and clinical research investigator for Galderma; consultant, advisor, and clinical research investigator for SkinMedica; consultant, speaker, and clinical research investigator for Alastin; honorarium recipient for Evolus; clinical research investigator for Recros Medica; and clinical research investigator, consultant, and stockholder for Glo Pharma; advisor and consultant for Teoxane; clinical research investigator for Symatese; and sponsored publication author for IQVIA/Endo. Dr. Montes is a speaker, trainer, clinical trial investigator, and advisor for AbbVie. Dr. Humphrey is a speaker, consultant, and investigator for AbbVie. Dr. Grunebaum is a consultant and researcher for AbbVie and Galderma. Dr. Bertossi receives research grants for investigator-initiated and sponsored trials and is a speaker and trainer for AbbVie. Dr. Dimitrijevic is a full-time employee of AbbVie and owns AbbVie stock. Dr. Sangha is a full-time employee of AbbVie. Allergan Aesthetics, an AbbVie Company, funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided to the authors by Regina Kelly, MA, of Peloton Advantage, LLC, an OPEN Health company, and funded by Allergan Aesthetics, an AbbVie Company.